We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Is there any cumulative dose for trastuzumab?
- Authors
Mutlu, Hasan; Coşkun, Hasan Şenol
- Abstract
Trastuzumab is one of the most important agents that target human epidermal growth factor receptor 2, but its cardiotoxic effect limits to use it. The mechanism of cardiac dysfunction-related trastuzumab is still unclear. In literature, there is no definite information about the cumulative dose of trastuzumab for cardiotoxicity. In presented case, we reported a breast cancer patient who has been receiving long-term trastuzumab. We have not found any cardiac problems for duration of over four years. According to our case and literature review, we may say that trastuzumab is safely used with periodically echocardiographic control in patients with breast cancer.
- Subjects
BREAST tumors; CARDIOTOXICITY; ECHOCARDIOGRAPHY; ONCOGENES; DOCETAXEL; TRASTUZUMAB; AROMATASE inhibitors
- Publication
Journal of Oncology Pharmacy Practice, 2015, Vol 21, Issue 6, p468
- ISSN
1078-1552
- Publication type
Article
- DOI
10.1177/1078155214538686